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Introduction: Non-invasive diagnostic tests for prostate cancer (PCa) are urgently needed, as 
measuring serum prostate specific antigen (PSA) has limitations of poor specificity and sensitivity and 
provides little long-term predictive information. Given the interest in exosomal RNA content in 
various cancers, we explored the potential utility of exosomal RNA as a basis for a diagnostic and 
prognostic tool for PCa. 
Methods: A panel of candidate exosomal microRNA (exomiR) biomarkers were established by 
performing an Affymetrix microRNA microarray using RNA extracted from several PCa cell lines 
(LNCaP, PC3, DU145 and VCaP) and transformed normal prostate epithelia (PNT2). These 
candidates were validated by qPCR. We then proceeded to gather urine and plasma samples from PCa 
patients before and following prostate removal surgery, and from healthy volunteers. After extensive 
optimisations in both body fluids we can present 3 methodologies for the extraction of exosomal 
miRNA from urine and plasma. 
Results:  PCa exosomes are highly enriched with miRNAs. We have identified a panel of exomiRs 
that differentiate cancerous from normal prostate cells.  Importantly, these exomiRs were able to 
define the androgen dependence status of our cell lines by qPCR analysis. We are currently 
attempting to translate these findings to the clinic by testing the utility of our unique exomiR panel in 
the detection of PCa in human urine and plasma.  Our preliminary data indicates that our candidate 
exomiR biomarker panel can differentiate between normal and PCa donor urine/plasma. 
Conclusions: Exosomal RNAs show great promise as diagnostic/prognostic biomarkers for PCa and 
will hopefully fill a significant gap in the clinical care of PCa patients.  
 
 
 
 
